Construction on the premises is anticipated to start this year. The completion of the building and the operational readiness of the various suites will happen in stages. Total investment volume until 2027, including land, buildings, technical equipment, and intangible assets may add up to 50 million Euros. If the process develops as envisaged, the facility is supposed to handle and manufacture a broad range of radioactive pharmaceutical and industrial products in its final stage. Eckert & Ziegler will be able to fund the development of the site through its regular cash-flow.
“The health system in China has made tremendous advances during the last decades”, explains Andreas Eckert, Founder and CEO of Eckert & Ziegler. “Innovative therapies for the treatment of cancer are more and more available now also to Chinese patients. As strategic supplier to many international oncology companies, Eckert & Ziegler needs to be present in China with its own broadly licensed radiation facility and a strong local team. The investment agreement executed with Jintan will bring us closer to this important objective”.
Eckert & Ziegler Strahlen- und Medizintechnik AG with more than 800 employees is one of the world’s largest providers of isotope-related components for nuclear medicine and radiation therapy. The company offers services for radiopharmaceuticals at various locations, from early development to commercialization. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.
Eckert & Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str. 10
13125 Berlin
Telefon: +49 (30) 941084-0
Telefax: +49 (30) 941084-112
http://www.ezag.de
Öffentlichkeitsarbeit
Telefon: +49 (30) 941084-138
Fax: +49 (30) 941084-112
E-Mail: karolin.riehle@ezag.de